ALGS Revenue Breakdown
Aligos Therapeutics, Inc. (ALGS). Quarter ended 2026-06-30 · 10-Q · every retained filed quarter remains available.
- 2025-12-31: Others Not split by product in the filing$2.19M100.00%; Total revenue $2.19M.
- 2024-12-31: Others Not split by product in the filing$3.61M100.00%; Total revenue $3.61M.
- 2023-12-31: Others Not split by product in the filing$6.19M100.00%; Total revenue $6.19M.
- 2022-12-31: Total revenue $0.00.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $2.19M 100.00% | $2.19M |
| 2024-12-31 | Not split by product in the filing $3.61M 100.00% | $3.61M |
| 2023-12-31 | Not split by product in the filing $6.19M 100.00% | $6.19M |
| 2022-12-31 | $0.00 | |
| 2021-12-31 | $0.00 | |
| 2020-12-31 | $0.00 |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $0.00 | $0.00 |
| 2026-03-31 | Not split by product $2.83M 100.00% | $2.83M |
| 2025-12-31 | Not split by product $169.00K 100.00% | $169.00K |
| 2025-09-30 | Not split by product $741.00K 100.00% | $741.00K |
| 2025-06-30 | Not split by product $965.00K 100.00% | $965.00K |
| 2025-03-31 | Not split by product $311.00K 100.00% | $311.00K |
| 2024-12-31 | Not split by product $606.00K 100.00% | $606.00K |
| 2024-09-30 | Not split by product $1.25M 100.00% | $1.25M |
| 2024-06-30 | Not split by product $1.06M 100.00% | $1.06M |
| 2024-03-31 | Not split by product $694.00K 100.00% | $694.00K |
| 2023-12-31 | Not split by product $672.00K 100.00% | $672.00K |
| 2023-09-30 | Not split by product $1.08M 100.00% | $1.08M |
| 2023-06-30 | Not split by product $4.29M 100.00% | $4.29M |
| 2023-03-31 | Not split by product $140.00K 100.00% | $140.00K |
| 2022-12-31 | Not split by product $0.00 | $0.00 |
| 2022-09-30 | Not split by product $0.00 | $0.00 |
| 2022-06-30 | Not split by product $0.00 | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |